Home / Lifestyle / Health & Fitness / Article / Anti-obesity drive, generic drugs to remain key focus in 2026

Anti-obesity drive, generic drugs to remain key focus in 2026

The market is expected to change radically in early 2026 following the patent expiration of semaglutide in India in March

  • WhatsAppBookmarkBookmark
Listen to this article :
Image for representational purpose only. Photo Courtesy: File pic

Image for representational purpose only. Photo Courtesy: File pic

From changing the definition to the rise of GLP-1 medications, and the government’s several initiatives, especially Prime Minister Narendra Modi's clarion call, obesity became the focus of healthcare in India in 2025. 

The anti-obesity drive, especially the generic drugs, will continue to remain a key focus in 2026.

Read Next Story
Hidden hormonal disorders are silently damaging male fertility, warn experts›

Trending Stories

Latest Photoscta-pos

Latest VideosView All

Latest Web StoriesView All

Mid-Day FastView All